



ATTORNEY DOCKET NO.: 2006164-0002 (BCF 10652-006)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Denis GRAVEL, *et al.*

Examiner: TBA

Serial No.: 10/537,146

Art Unit: TBA

Filing Date: June 2, 2005

Title: **DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND
ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX**

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- ☒ An *original* Information Disclosure Statement; or
- ☐ A *supplemental* Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

11/22/05
Date

Justin Blanch
Signature

Justin Blanch
Name of Person Signing

RECEIVED
DEC 5 2005
TECH CENTER 1600/2600



RECEIVED
DEC - 5 2005
TECH CENTER 1600/2900

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☒ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the

information disclosure statement was known to any individual
designated in § 1.56(c) more than three months prior to the filing
of
the information disclosure statement; or

☐ Includes herewith the fee set forth in § 1.17(p),

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under
§ 1.113, a notice of allowance under § 1.311, or an action that otherwise closes
prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure
statement was first cited in any communication from a foreign
patent office in a counterpart foreign application not more than
three months prior to the filing of the information disclosure
statement; or

☐ That no item of information contained in the information
disclosure statement was cited in a communication from a foreign
patent office in a counterpart foreign application, and, to the
knowledge of the person signing the certification after making
reasonable inquiry, no item of information contained in the
information disclosure statement was known to any individual
designated in § 1.56(c) more than three months prior to the filing
of
the information disclosure statement; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with an asterisk is included;
- ☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☐ Does not contain non-English language citations;
- ☐ Includes one or more translations of a non-English citation; or
- ☒ Does contain non-English language citations, of which the following is a concise explanation: Translation may be provided upon request.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC §102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Dated: November 22, 2005

CHOATE, HALL & STEWART, LLP
2 International Place
Boston, Massachusetts 02110
(617) 248-5000
(617) 248-4000

Respectfully submitted,

Charles Lyon Ph.D.
Reg. No. 56,630

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant: Denis Gravel, et al.

Filing Date: June 2, 2005

Group:

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	EP 0254 032	Europe	27 January 1988		
	EP 0412 595	Europe	13 February 1991		
	EP 0566 157	Europe	20 October 1993		
	FR 2 372 804	France	30 June 1978		X
	FR 2 377 374	France	11 August 1978		X
	WO 97/05865	International	20 February 1997		
	WO 99/11606	International	11 March 1999		
	WO 00/50580	International	31 August 2000		
	WO 02/092128	International	21 November 2002		
	WO 02/15918	International	28 February 2002		
	WO 03/084997	International	16 October 2003		

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	ADHR Consortium, et al., "Autosomal Dominant Hypophosphataemic Rickets Is Associated With Mutations In FGF23" <i>Nat. Genetic</i> 26: 345-348, 2000.
	Atherton in <i>The Peptides</i> , S. Udenfriend and J. Meienhofer, editors. Vol. 9, p.1, Academic Press, New York. (1987)
	Balkenhohl, et al., "Combinatorial Synthesis Of Small Organic Molecules" <i>Angew. Chem. Int. Ed. Engl.</i> 35: 2288-2337, 1996.
	Beck, et al., "Pex/PEX Tissue Distribution And Evidence For A Deletion In The 3' Region Of The Pex Gene In X-Linked Hypophosphatemic Mice" <i>J. Clin. Invest.</i> 99: 1200-1209, 1997.

INFORMATION DISCLOSURE STATEMENT

(Use separate sheets if necessary)

Applicant: Denis Gravel, *et al.*Filing Date: June 2,
2005

Group:

RECEIVED
DEC 5 2005
TECH CENTER 1600/2500

- Bellos, et al., "Mineralized Bone Nodules Formed *In Vitro* From Enzymatically Released Rat Calvaria Cell Populations" *Calcif. Tissue Int.* **38**: 143-154, 1986.
- Boileau, et al., "Characterization Of PHEX Endopeptidase Catalytic Activity: Identification Of Parathyroid-Hormone-Related Peptide As A Substrate And Osteocalcin, PP and Phosphate As Inhibitors" *Biochem J.* **355**: 707-713, 2001.
- Chapman, et al., "Inhibition Of Matrix Metalloproteinases By N-Carboxyalkyl Peptides " *Journal Of Medicinal Chemistry* **36(26)**: 4293-301, 1993
- Chapman, et al., "Inhibition Of Matrix Metalloproteinases By N-Carboxyalkyl Peptides " *Journal Of Medicinal Chemistry* **36(26)**: 4293-301, 1993. . (Supplementary Material)
- Fournie-Zaluski, et al., "Differential Recognition Of 'Enkephalinase' And Angiotensin-Converting Enzyme By New Carboxyalkyl Inhibitors" *Life Sciences* **31**: 2947-2954, 1982.
- Du, et al., "CDNA Cloning Of The Murine PeX Gene Implicated in X-Linked Hypophosphatemia And Evidence For Expression In Bone" *Genomics* **36**: 22-28, 1996.
- Ecarot, et al., "Defective Bone Formation By Hyp Mouse Bone Cells Transplanted Into Normal Mice: Evidence In Favor Of An Intrinsic Osteoblast Defect" *Journal Of Bone And Mineral Research* **7**: 215-220, 1992.
- Econs, et al., "Tumor Induced Osteomalacia -Unveiling a New Hormone" *N. Engl. J. Med.* **330**: 1679-1681, 1994.
- Elgazwy, et al., "Facile Synthesis Of (R,R) And Of (R,S) Tricarballic Acid Anhydride And Amide Derivatives" *Molecules* **5(4)**: 665-673, 2000. (Abstract Only)
- Furka A (1996) in *Combinatorial Peptide and Nonpeptide Libraries*. G. Jung, editor, Ch. 4, pp. 111-137, VCH Verlagsgesellschaft, Weinheim.
- Greene TW, Wuts PG (1999) *Protective Groups In Organic Synthesis*, John Wiley & Sons, Inc., New York.
- Grieff, et al., "Expression And Cloning Of The Human X-Linked Hypophosphatemia Gene cDNA" *Biochem. Biophys. Res. Commun.* **231**: 635-639, 1997.
- Guo, et al., "Cloning And Sequencing Of Human PEX From A Bone CDNA Library: Evidence For Its Developmental Stage-Specific Regulation In Osteoblasts" *J. Bone Miner. Res.* **12**: 1009-1017, 1997.
- Hermkens, et al., "Solid-Phase Organic Reactions: A Review Of The Recent Literature" *Tetrahedron* **52**: 4527-4554, 1996.
- Ikeuchi, et al., "Recombinant Human Bone Morphogenetic Protein-2 Promotes Osteogenesis Within Atelopeptide Type I Collagen Solution By Combination With Rat Cultured Marrow Cells." *J. Biomed. Mater. Res.* **60**: 61-69, 2002.
- Jan de Beur, et al., "Tumors Associated With Oncogenic Osteomalacia Express Genes Important In Bone And Mineral Metabolism" *J. Bone Miner. Res.* **17**: 1102-1110, 2002.
- Jonsson, et al., ASBMR 24th Annual Meeting In San Antonio, Texas, USA, 2002 (Presentation # 1139).
- Lajeunesse, et al., "Direct Demonstration Of A Humorally-Mediated Inhibition Of Renal

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2006164-0002 PCF 10652-006)	In re Application No. 10/537,146 Applicant: Denis Gravel, <i>et al.</i> Filing Date: June 2, 2005 Group:
---	---	---	---

	Phosphate Transport In The <i>Hyp</i> Mouse." <i>Kidney Int.</i> 50 : 1531-1538, 1996.
	Lipman, et al., "Cloning Of Human PEX cDNA" <i>J. Biol. Chem.</i> 273 : 13729-13737, 1998.
	Mimura, et al., "A Novel Class Of Enkephalinase Inhibitors Containing A C-Terminal Sulfo Group" <i>J. Med. Chem.</i> 35 : 602-608, 1992.
	Nesbitt, et al., "Coordinated Maturation Regulation Of PHEX And Renal Phosphate Transport Inhibitory Activity: Evidence For The Pathophysiological Role Of PHEX In X-Linked Hypophosphatemia" <i>Bone Miner Res.</i> 14 : 2027-2035, 1999.
	Ovens, et al., "Design And Synthesis Of Acidic Dipeptide Hydroxamate Inhibitors Of Procollagen C-Proteinase" <i>Journal Of Peptide Science</i> 6(9) : 489-495, 2000.
	Rinnova, et al., "An Expedient method For The Solid-Phase Synthesis Of Alpha -Aminoalkyl Phosphonopeptides" <i>Tetrahedron Letters</i> 43(22) : 4103-4106, 2002
	Rivero, RA, Greco MN, Maryanoff B (1997) in <i>A Practical Guide To Combinatorial Chemistry</i> . AW Czarnik, SH DeWitt, editors. Ch. 10, pp. 281-307, American Chemical Society Publication, Washington DC.
	Roques, et al., "Neutral Endopeptidase 24.11: Structure, Inhibition, And Experimental And Clinical Pharmacology" <i>Pharmacological Reviews</i> 45 : 87-146, 1993.
	Rowe, et al., "MEPE, A New Gene Expressed In Bone Marrow And Tumors Causing Osteomalacia" <i>Genomics</i> , 67 : 54-68, 2000.
	Rowe, et al., "The Role Of The PHEX Gene (PEX) In Families With X-Linked Hypophosphataemic Rickets" <i>Current Opinion In Nephrology and Hypertension</i> 7 : 367-376, 1998.
	Ruchon, et al., "Pex mRNA Is Localized IN Developing Mouse Osteoblasts and Odontoblasts" <i>J. Histochem. Cytochem.</i> 46 : 459-468, 1998.
	Ruchon, et al., "Developmental Expression And Tissue Distribution Of Phex Protein: effect Of The Hyp Mutation And Relationship To Bone Markers." <i>J. Bone Miner. Res.</i> 15 : 1440-1450 2000.
	Schiavi, et al., "Phosphatonins: A New Class Of Phosphate-Regulating Proteins" <i>Curr. Opin. Nephro. Hypertens</i> 11 : 423-430, 2002.
	Serval, et al., "In Vitro And In Vivo Inhibition Of n-Acetyl-L-Aspartyl-L-Glutamate Catabolism By N-Acylated L-Glutamate Analogs" <i>Journal Of Pharmacology And Experimental Therapeutics</i> 260(3) : 1093-1100, 1992.
	Shimada, et al., "Cloning And Characterization Of FGF23 As A Causative Factor Of Tumor-Induced Osteomalacia" <i>Proc. Natl. Acad. Sci. USA</i> 98 : 6500-6505, 2001.
	Strom, et al., "Pex Gene Deletions In Gy And Pyh Mice Provide Mouse Models For X-Linked Hypophosphatemia" <i>Hum. Mol. Genet.</i> 6 : 165-171, 1997.
	Tenenhouse, et al., "X-Linked Hypophosphataemia: A Homologous Disorder In Humans And Mice" <i>Nephrol Dial Transplant</i> 14 : 333-341, 1999.
	Tenenhouse HS, Econs MJ (2001) in <i>The Metabolic and Molecular Bases of Inherited Disease</i> . CR Scriver, AL Beaudet, WS Sly, D Valle, editors. Ch. 197, pp. 5039-5067, McGraw Hill Brook Co., New York.
	Terret, et al., "Combinatorial Synthesis—The Design Of Compound Libraries And Their

Form PTO-1449 (REV. 8-83) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Atty. Docket: 2006164-0002 (SCF 10652-006)	In re Application No. 10/537,146
	Applicant: Denis Gravel, et al.	
	Filing Date: June 2, 2005	Group:

	Application To Drug Discovery" <i>Tetrahedron</i> 51 : 8135-8173, 1995.
	The HYP Consortium " A Gene (PEX) With Homologies To Endopeptidases Is Mutated In Patients With X-Linked Hypophosphatemic Rickets" <i>Nat. Genet.</i> 11 : 130-136, 1995.
	Thompson, et al., "Synthesis And Applications Of Small Molecule Libraries" <i>Chem. Rev.</i> 96 : 555-600, 1996.
	Turner, et al., "Mammalian Membrane Metallopeptides: NEP, ECE, KELL, And PEX" <i>FASEB J.</i> 11 : 355-364, 1997.
	Vehof, et al., "Ectopic Bone Formation In titanium Mesh Loaded With Bone Morphogenetic Protein And Coated With Calcium Phosphate" <i>Plast. Reconstr. Surg.</i> 108 : 434-443, 2001.
	Vu, et al., "In Vivo Model For The Experimental Manipulation Of Calcified Tissues: A Surgical Approach For Accessing The Odontogenic Organ And Associated Tissues Of The Rat Incisor" <i>J Histochem. Cytochem.</i> 47 : 323-336, 1999.
	Whittaker, et al., "Design And Therapeutic Application Of Matrix Metalloproteinase Inhibitors" <i>Chem. Rev.</i> 99 : 2735-2776, 1999.
	Yoshida, et al., "Enhancement By Recombinant Human Bone Morphogenetic Protein-2 Of Bone Formation By Means Of Porous Hydroxypatite In Mandibular Bone Defects" <i>J Dent. Res.</i> 78 : 1505-1510, 1999.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4005335v1